Effect of a Selective Abl Tyrosine Kinase Inhibitor, STI571, on in Vitro Growth of BCR-ABL-positive Acute Lymphoblastic Leukemia Cells

Leukemia - United Kingdom
doi 10.1038/sj.leu.2402068
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

Haematologica
Hematology
2015English

Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571

Clinical Cancer Research
Cancer ResearchOncology
2006English

BCR-ABL Tyrosine Kinase

Science-Business eXchange
2012English

Treatment of BCR/Abl-Positive Acute Lymphoblastic Leukemia in P190 Transgenic Mice With the Farnesyl Transferase Inhibitor SCH66336

Blood
BiochemistryImmunologyCell BiologyHematology
2001English

Immunologic Characterization of the Tumor-Specific BCR-Abl Junction in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
1990English

Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL-induced B-Cell Acute Lymphoblastic Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2019English

Nilotinib Treatment in Mouse Models of P190 BCR/Abl Lymphoblastic Leukemia

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2007English

Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia

Oncotarget
Oncology
2018English

Acute Myeloid Leukemia With BCR/ABL Fusion Chimera

Indian Journal of Hematology and Blood Transfusion
Hematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy